Salesforce CRM Expands Agent Fabric to Serve as MultiVendor AI Control Plane OpenAI Reportedly Poised for Confidential IPO Filing Signaling FirstMover Advantage in AI Sector Translational Development Acquisition Corp Files Proxy Statement for Shareholder Meeting US Advocacy Groups Call for Investigation into Roblox Over Child Safety and InGame Spending Concerns Patient Capital Trusts India as Hot Money Exits FDI Inflow Jumps 17 YoY to 945 Billion in FY26 Federal Reserve Faces Diminishing Case for Interest Rate Cuts Amid Strong Labor Market and Stubborn Inflation PDCC Q4 2025 Earnings Slight EPS Miss Amid Credit Market Uncertainty AGNC Investment Corp Q1 2026 Earnings Solid EPS Beat Amid Challenging Rate Environment urbangro Inc UGRO Q3 2025 Earnings Staggering Loss Shocks Market Amid Missing Revenue Data Kinsale Capital Group Q1 2026 Earnings Strong EPS Beat Belied by Modest Share Decline NE Q1 2026 Earnings EPS Beats Estimates by 301 Stock Declines DIBS Q1 2026 Earnings NarrowerThanExpected Loss Fails to Lift Sentiment Futu Holdings FUTU Slumps 275 as Key Support Levels Come Into Focus Alarum Technologies ALAR Surges 298 as Shares Test Key Resistance Immunic Inc IMUX Rally Continues with 879 Gain Approaching Key Resistance NextTrip Inc NTRP Rallies 348 as Stock Tests Key Resistance at 250 OR Royalties Inc OR Slips 33 as Price Tests Key Support Levels Gold Mining Sectors Q1 Earnings Suggest Bullish Momentum May Persist KRT Q1 2026 Earnings EPS Beats Estimates by Over 12 as Shares Edge Lower Viewbix Inc VBIX Holds Steady at 364 Key Support and Resistance Levels in Focus NGL Q1 2026 Earnings EPS Misses Estimates Despite Positive Stock Movement MTEX Q3 2023 Earnings Narrow Profit as Stock Gains COCH Q1 2026 Earnings Narrower Loss Beats Estimates as Envoy Medical Advances RWAY Q1 2026 Earnings EPS Falls Short of Analyst Expectations NexGen Energy NXE Q1 2026 Earnings Substantial EPS Miss Highlights PreRevenue Development Phase Halozyme Therapeutics Q1 2026 Earnings EPS Beat Drives Modest Positive Surprise Despite Flat Revenue Disclosure Lantern Pharma LTRN Q1 2026 Earnings EPS Beats Estimates by 183 Despite Absence of Revenue